ImmunityBio reported roughly $113 million in net product revenue for 2025, a 700% year-over-year increase driven by ANKTIVA adoption.
The Saudi FDA granted accelerated approval for ANKTIVA in bladder cancer and non-small cell lung cancer, marking the first global solid-tumor approval for the drug.
Reddit discussion across r/Shortsqueeze and r/pennystocks focused on short interest near 50% and the potential for a squeeze, with many users expressing bullish price targets.
ANKTIVA Revenue Growth Drives the Narrative
The primary catalyst cited across Reddit posts and news articles alike was ImmunityBio’s preliminary full-year 2025 results. The company reported approximately $113 million in net product revenue, a 700% year-over-year increase, with Q4 2025 alone contributing $38.3 million. An
The revenue figures transformed the stock from a speculative biotech play into a story about tangible top-line growth, a shift that resonated with retail traders who had previously watched the stock trade in penny-stock territory.
Saudi FDA Approval Widens the Addressable Market
On the same day, the Saudi FDA granted accelerated approval for ANKTIVA in both bladder cancer and non-small cell lung cancer. Reddit users in r/Shortsqueeze pointed to the announcement from Dr. Pat Soon-Shiong as a reason for optimism, with one post noting that the approval “should set up even more revenue and also provide data for additional adoption in other countries.” The lung cancer indication is particularly significant because it marks the first global approval for ANKTIVA in a solid tumor outside of bladder cancer, potentially opening a much larger patient population.
Short Squeeze Speculation Adds Fuel
A recurring theme in the Reddit discussion was short interest. Posts on r/Shortsqueeze claimed that “shorts just dumped remaining shares” and that available shares to short had dropped to zero, setting up a potential squeeze. A r/pennystocks user estimated short interest at nearly 50%, while a separate post on the same subreddit expected the stock to reach $6–$7 “due to a successful short squeeze.” A Benzinga article published that morning placed
Beyond the Squeeze: Durable Clinical Data
Among the posts on r/stocks, a user highlighted a separate clinical development: durable complete responses in Waldenstrom Non-Hodgkin Lymphoma patients treated with ImmunityBio’s immunotherapy. The post noted that “all remain in clinical disease control” and that two patients demonstrated “durable complete remission at 7 and 15 months.” While this news was not a same-day catalyst, it contributed to the broader thesis that the company’s platform has applications beyond bladder cancer.
From a retail-investor perspective, the confluence of revenue growth, regulatory expansion, and squeeze mechanics created a rare alignment of fundamental and speculative catalysts. That alignment drove
Subscribe to Tendie.bot for more market recaps.